ANI Pharmaceuticals Inc. (ANIP)
Stock · NASDAQ · Health Care
$72.19as of 10/16/2026
Price chart
Active signals
ANIP Signal Track Record
How signals performed across all stocks →What ANIP's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 35 | +2.2% | 66% | September 1, 2026 |
| 200-Day Moving Average TouchActive now | 22 | +0.7% | 50% | September 21, 2026 |
| Bollinger Band Breakout | 21 | -1.8% | 48% | September 21, 2026 |
| Bollinger Band Breakdown | 21 | +0.2% | 52% | August 10, 2026 |
| Any 20-session window (baseline) | +1.0% | 55% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ANIP
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The comp…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 970
- Website
- www.anipharmaceuticals.com/
Fundamentals
- 1-day range
- $71.5$73.08
- Market cap
- $1.86B
- P/E (trailing)
- 15.16
- P/E (forward)
- 7.11
- EPS (trailing)
- $5.00
- Dividend yield
- —
- Beta
- 0.47
- Avg. volume
- 380.0K
How ANI Pharmaceuticals Inc. Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 27, 2026 · via SEC EDGAR / Finnhub
Forecasts
9 analyst ratings
ANI Pharmaceuticals Inc. Competitors
Chosen by industry and closest market cap.
- ANIPANI Pharmaceuticals Inc.$72.29▲ 0.01%Market cap $1.86BP/E 15.16$69.58$97
- NAMSWNewAmsterdam Pharma Company N.V. Warrant$9▼ 17.81%Market cap $1.87BP/E —$9.79$30.45
- DMRADamora Therapeutics Inc. Ordinary Shares$18.44▼ 1.60%Market cap $1.84BP/E —$16.5$34.89
- NBTXNanobiotix S.A. American Depositary Shares$21.3▼ 4.18%Market cap $1.83BP/E —$13.1$47.66
- CMPSCOMPASS Pathways Plc American Depository Shares$10.75▼ 7.49%Market cap $1.83BP/E —$4.88$15.87
- BCAXBicara Therapeutics Inc. Common Stock$16.78▼ 4.77%Market cap $1.81BP/E —$13.7$30.99
- AGIOAgios Pharmaceuticals Inc. Common Stock$31.32▼ 3.09%Market cap $1.91BP/E —$22.24$46
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ANIP ANI Pharmaceuticals Inc. | $1.86B | 15.16 | $72.29 | ▲ 0.01% | $69.58$97 |
| NAMSW NewAmsterdam Pharma Company N.V. Warrant | $1.87B | — | $9 | ▼ 17.81% | $9.79$30.45 |
| DMRA Damora Therapeutics Inc. Ordinary Shares | $1.84B | — | $18.44 | ▼ 1.60% | $16.5$34.89 |
| NBTX Nanobiotix S.A. American Depositary Shares | $1.83B | — | $21.3 | ▼ 4.18% | $13.1$47.66 |
| CMPS COMPASS Pathways Plc American Depository Shares | $1.83B | — | $10.75 | ▼ 7.49% | $4.88$15.87 |
| BCAX Bicara Therapeutics Inc. Common Stock | $1.81B | — | $16.78 | ▼ 4.77% | $13.7$30.99 |
| AGIO Agios Pharmaceuticals Inc. Common Stock | $1.91B | — | $31.32 | ▼ 3.09% | $22.24$46 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Did FDA Approval of Generic Everolimus Suspension Just Shift ANI Pharmaceuticals' (ANIP) Investment Narrative?Yahoo · 10/7/2026
- 1 Safe-and-Steady Stock with Competitive Advantages and 2 We Turn DownYahoo · 10/6/2026
- 1 Small-Cap Stock for Long-Term Investors and 2 We IgnoreYahoo · 10/1/2026
- ANI Pharmaceuticals Announces New Fluocinolone Acetonide Intravitreal Implant Data to be Presented at the American Academy of Ophthalmology 2026 Annual MeetingYahoo · 9/30/2026
- 3 Profitable Stocks Worth InvestigatingYahoo · 9/29/2026
- Implied Volatility Surging for ANI Pharmaceuticals Stock OptionsYahoo · 9/28/2026
- ANI Pharmaceuticals: Cortrophin's Q4 Test, With Generics Funding The BuildSeekingAlpha · 9/24/2026
- Ocular Therapeutix and ANI Pharmaceuticals Stocks Trade Down, What You Need To KnowYahoo · 9/23/2026
Insider Activity
Insider Actions →- Nikhil Lalwani · September 15, 2026 · Sale5.4K @ $71
- Meredith Cook · September 14, 2026 · Sale500 @ $70.79
- Jeanne Thoma · September 11, 2026 · Sale1.0K @ $71.53
- Stephen P. Carey · August 31, 2026 · Sale2.9K @ $72.8
- Nikhil Lalwani · August 25, 2026 · Sale5.4K @ $74.3
- Gosebruch Henry O · August 19, 2026 · Grant6.7K
- Meredith Cook · August 13, 2026 · Sale500 @ $75.48
- Ori Gutwerg · August 10, 2026 · Sale3.2K @ $77
- Stephen P. Carey · July 29, 2026 · Sale2.9K @ $81.36
- Meredith Cook · July 18, 2026 · Tax Withholding2.5K @ $79.2
- Meredith Cook · July 13, 2026 · Sale500 @ $81.84
- Stephen P. Carey · July 2, 2026 · Option Exercise3.3K @ $49.51
- Stephen P. Carey · July 2, 2026 · Sale3.3K @ $86
- Meredith Cook · June 12, 2026 · Sale500 @ $82.03
- Thomas Haughey · June 8, 2026 · Sale2.0K @ $80.88
Institutional Ownership
March 31, 2026
- Total shares held
- 23.18M
- Total value held
- $1.75B
- Institutional holders
- 272
- Unknown2.75M
- Unknown823.1K
- Unknown820.2K
- Unknown771.6K
- Unknown707.5K
- Unknown668.0K
- Unknown600.0K
- Unknown592.0K
- Unknown564.4K
- Unknown535.9K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
ANI Pharmaceuticals Reports Positive Phase 4 Trial Results
ANI Pharmaceuticals announced encouraging results from its Phase 4 open‑label SYNCHRONICITY study, presented at the American Academy of Ophthalmology meeting. The company’s focus on this therapy comes amid a recent FDA pause on generic everolimus, which may alter market perception of its product line. Analysts note ANI’s competitive advantages, though the stock remains near its 52‑week low, suggesting cautious evaluation.
ANI Pharmaceuticals Reports Positive Phase 4 Trial Results. ANI Pharmaceuticals announced encouraging results from its Phase 4 open‑label SYNCHRONICITY study, presented at the American Academy of Ophthalmology meeting. The company’s focus on this therapy comes amid a recent FDA pause on generic everolimus, which may alter market perception of its product line. Analysts note ANI’s competitive advantages, though the stock remains near its 52‑week low, suggesting cautious evaluation.